Latest News
Charter Communications Shares Tumble 22% as Broadband Losses Double
Charter Communications shares fell 22% after reporting 120,000 broadband customer losses in Q1, double last year's figure and worse than analyst expectations.
Lilly's Oral Obesity Drug Foundayo Trails Novo Nordisk's Wegovy in Early Prescription Data
Eli Lilly's Foundayo prescriptions hit 3,707 in week two, well behind Novo Nordisk's Wegovy. Lilly shares dropped 4%, while Novo gained 6%. Analysts advise caution on early figures.
Cheetah Net Soars on Acquisition Deal, Heavy Trading Volume
Cheetah Net shares jumped on heavy volume after agreeing to buy Super International Trading for $4.98M in cash, with a $10M annual revenue target.
Keel Infrastructure Sells Paraguay Site for $13M, Exits Latin America
Keel Infrastructure sold its Paraguay facility for $13M, less than half the original price, completing its Latin American exit and shift toward AI data centers.
Tempus AI Partners with USC Health System, Unlocking Access to 1.5 Million Annual Visits
Tempus AI Inc. partners with USC's Keck School of Medicine to deploy its molecular testing and trial-matching platform across a health system seeing 1.5 million patient visits each year.
FreeCast Soars on DIRECTV Multifamily Deal, Financing Risks Remain
FreeCast shares jumped 23.8% on a DIRECTV multifamily deal. Maxim Group initiated with Buy and $6 target. Dilution risks persist per SEC filings.
Novo Nordisk Wegovy Pill Prescriptions Surge Past Eli Lilly's Foundayo in Early Launch Race
Novo Nordisk's Wegovy pill recorded 18,410 U.S. prescriptions in its second week, far outpacing Eli Lilly's Foundayo at 3,707, according to IQVIA data. Novo shares rose, Lilly fell.
POET Rockets 27% on Marvell Order Hopes, AI Optics Frenzy
POET Technologies shares jumped 27% after the CFO mentioned a purchase order tied to Marvell, reigniting AI optics enthusiasm despite a thin revenue base.
Elong Power Stock Surges 26% on Heavy Volume Amid Turnaround Efforts
Elong Power shares surged 26% on heavy trading volume, as the company released its annual report showing narrowed losses and a strategic pivot to an asset-light battery storage model.
Scinai Immunotherapeutics Soars 82% on $2.61M Private Placement for CDMO Expansion
Scinai Immunotherapeutics shares surged 82% after announcing a $2.61M private placement to support its CDMO expansion and immunotherapy programs.